PMID- 33026266
OWN - NLM
STAT- MEDLINE
DCOM- 20210427
LR  - 20210427
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 62
IP  - 2
DP  - 2021 Feb
TI  - Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter 
      study.
PG  - 330-336
LID - 10.1080/10428194.2020.1827241 [doi]
AB  - We present a retrospective multicenter study of pralatrexate treatment outcomes 
      in an Australian practice setting for patients with relapsed/refractory T-cell 
      lymphoma who had failed 1+ systemic therapies, treated via a compassionate access 
      program. Endpoints assessed included response rates, toxicities, and subsequent 
      therapies. Progression-free survival (PFS), time to next treatment (TTNT), 
      event-free survival (EFS), overall survival (OS), and time to best response, were 
      assessed by Kaplan-Meier analysis. The study included 31 patients, with median 
      age 69 years. We demonstrated ORR of 35.5% (n = 11), including 4 complete 
      responses (13%) and 7 partial responses (23%). The predicted median OS was 10 
      months, with EFS of 9 months, and PFS of 9 months. Median TTNT was 8 months. 
      Mucositis was the most commonly observed toxicity. This study - the second 
      largest real-world cohort reported to date - underscores the importance of 
      pralatrexate in relapsed/refractory T-cell lymphoma, as well as its acceptable 
      toxicity profile.
FAU - Bhurani, Mansi
AU  - Bhurani M
AD  - Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, 
      Australia.
AD  - Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, 
      VIC, Australia.
AD  - Faculty of Medicine, Nursing, and Health Sciences, Monash University, Melbourne, 
      VIC, Australia.
FAU - Admojo, Lorenz
AU  - Admojo L
AD  - Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, 
      Australia.
AD  - Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, 
      VIC, Australia.
FAU - Van Der Weyden, Carrie
AU  - Van Der Weyden C
AD  - Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, 
      Australia.
AD  - Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, 
      VIC, Australia.
FAU - Twigger, Robert
AU  - Twigger R
AD  - Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, 
      Australia.
AD  - Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, 
      VIC, Australia.
FAU - Bazargan, Ali
AU  - Bazargan A
AUID- ORCID: 0000-0001-6566-6215
AD  - St Vincent's Health, Melbourne, VIC, Australia.
FAU - Quach, Hang
AU  - Quach H
AUID- ORCID: 0000-0002-4796-3352
AD  - St Vincent's Health, Melbourne, VIC, Australia.
FAU - Zimet, Allan
AU  - Zimet A
AD  - Epworth Healthcare, Melbourne, VIC, Australia.
FAU - Coyle, Luke
AU  - Coyle L
AD  - Royal North Shore Hospital, Sydney, NSW, Australia.
FAU - Lindsay, Julian
AU  - Lindsay J
AD  - Royal North Shore Hospital, Sydney, NSW, Australia.
FAU - Radeski, Dejan
AU  - Radeski D
AD  - Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
FAU - Hawkes, Eliza
AU  - Hawkes E
AD  - Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, VIC, 
      Australia.
FAU - Kennedy, Glen
AU  - Kennedy G
AD  - Mater Cancer Care Centre, Brisbane, QLD, Australia.
FAU - Irving, Ian
AU  - Irving I
AD  - Icon Cancer Care, Brisbane, QLD, Australia.
FAU - Gutta, Naadir
AU  - Gutta N
AD  - Icon Cancer Care, Brisbane, QLD, Australia.
FAU - Trotman, Judith
AU  - Trotman J
AD  - Concord Hospital, Sydney, NSW, Australia.
FAU - Yeung, James
AU  - Yeung J
AD  - Concord Hospital, Sydney, NSW, Australia.
AD  - Royal Prince Alfred Hospital, Sydney, NSW, Australia.
FAU - Dunlop, Lindsay
AU  - Dunlop L
AD  - Southern Highland Private Hospital, Liverpool, NSW, Australia.
FAU - Hua, Minh
AU  - Hua M
AD  - Royal Prince Alfred Hospital, Sydney, NSW, Australia.
FAU - Giri, Pratyush
AU  - Giri P
AD  - Royal Adelaide Hospital, Adelaide, SA, Australia.
FAU - Yuen, Sam
AU  - Yuen S
AD  - Calvary Mater, Newcastle, NSW, Australia.
FAU - Panicker, Shyam
AU  - Panicker S
AD  - Hills Specialist Group, Bella Vista, NSW, Australia.
FAU - Moreton, Susan
AU  - Moreton S
AD  - Dubbo Base Hospital, Dubbo, NSW, Australia.
FAU - Khoo, Liane
AU  - Khoo L
AD  - Royal Prince Alfred Hospital, Sydney, NSW, Australia.
FAU - Scott, Ashleigh
AU  - Scott A
AD  - Royal Brisbane and Women's Hospital, Herston, QLD, Australia.
AD  - Sir Peter MacCallum Department of Surgical Oncology, Parkville, VIC, Australia.
FAU - Kipp, David
AU  - Kipp D
AD  - Barwon Health Cancer Services, Geelong, VIC, Australia.
FAU - McQuillan, Andrew
AU  - McQuillan A
AD  - Hollywood Medical Centre, Nedlands, WA, Australia.
FAU - McCormack, Chris
AU  - McCormack C
AD  - Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, 
      Australia.
AD  - Sir Peter MacCallum Department of Surgical Oncology, Parkville, VIC, Australia.
FAU - Dickinson, Michael
AU  - Dickinson M
AD  - Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, 
      Australia.
AD  - Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, 
      VIC, Australia.
FAU - Prince, Henry Miles
AU  - Prince HM
AD  - Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, 
      Australia.
AD  - Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, 
      VIC, Australia.
AD  - Faculty of Medicine, Nursing, and Health Sciences, Monash University, Melbourne, 
      VIC, Australia.
AD  - Epworth Healthcare, Melbourne, VIC, Australia.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20201007
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (10-propargyl-10-deazaaminopterin)
RN  - JYB41CTM2Q (Aminopterin)
SB  - IM
MH  - Aged
MH  - Aminopterin/analogs & derivatives
MH  - Australia/epidemiology
MH  - Humans
MH  - *Lymphoma, T-Cell/drug therapy
MH  - *Neoplasm Recurrence, Local/drug therapy
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Pralatrexate
OT  - T-cell lymphoma
OT  - cutaneous T-cell lymphoma
OT  - mucositis
OT  - peripheral T-cell lymphoma
EDAT- 2020/10/08 06:00
MHDA- 2021/04/28 06:00
CRDT- 2020/10/07 12:09
PHST- 2020/10/08 06:00 [pubmed]
PHST- 2021/04/28 06:00 [medline]
PHST- 2020/10/07 12:09 [entrez]
AID - 10.1080/10428194.2020.1827241 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2021 Feb;62(2):330-336. doi: 10.1080/10428194.2020.1827241. Epub 
      2020 Oct 7.